Regeneron Plummets On Early Phase III Results With Axokine
By Randall Osborne
Tuesday, April 1, 2003
Preliminary results from Regeneron Pharmaceutical Inc.'s Phase III trial with the obesity drug Axokine are being called mixed, but the market's reaction was unambiguous, taking away 56.6 percent of the stock's value.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.